Showing 1431-1440 of 1621 results for "".
- BVI Expands Portfolio with New Viscoelastic; Forges Strategic Partnership with Cromahttps://modernod.com/news/bvi-expands-portfolio-with-new-viscoelastic-forges-strategic-partnership-with-croma/2477789/BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market. Terms of the deal were not
- Visibly Offers Free Telehealth Vision Tests During COVID-19 Pandemichttps://modernod.com/news/visibly-offers-free-telehealth-vision-tests-during-covid-19-pandemic/2477627/Visibly announced that it will globally provide optometrists, ophthalmologists, and optical service providers free access to its virtual vision test technology to ensure that patients can meet their eye health needs during this unprecedented time. “We are thrilled to offer Visibly to all d
- ProtoKinetix AAGP Exhibits Efficacy and Safety in Model of Dry Eye Diseasehttps://modernod.com/news/protokinetix-aagp-exhibits-efficacy-and-safety-in-model-of-dry-eye-disease/2479530/ProtoKinetix, which recently announced filing for patent protection for new applications of its AAGP (PKX-001) molecule, announced preliminary results in efficacy and safety for use in treating dry eye disease (DED). PKX-001 demonstrated a protective effect in the murine model of dry eye d
- ARVO Annual Meeting Cancelledhttps://modernod.com/news/arvo-annual-meeting-cancelled/2477380/Due to the COVID-19 outbreak, the Board of Trustees at The Association for Research in Vision and Ophthalmology (ARVO) has decided to cancel its annual meeting, scheduled to take place May 1–7 in Baltimore. The ARVO organizers released an emailed statement to its membership outlining the d
- EyePoint Pharmaceuticals Announces Positive Topline 36-Month Follow-up Data for Second Phase 3 Study of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-36-month-follow-up-data-for-second-phase-3-study-of-yutiq/2477336/EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second phase 3 trial of Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. “The d
- Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for AMDhttps://modernod.com/news/gemini-therapeutics-and-singapore-eye-research-institute-enter-into-research-collaboration-to-explore-new-targets-for-amd/2477327/Gemini Therapeutics announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and potential biomarkers in patients d
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- Leica Microsystems and Precision Lens Sign Agreement to Expand Leica Ophthalmic Portfolio in the U.S. Midwesthttps://modernod.com/news/leica-microsystems-and-precision-lens-sign-agreement-to-expand-leica-ophthalmic-portfolio-in-the-u-s-midwest/2477077/Leica Microsystems and Cameron Ehlen Group, d/b/a Precision Lens, have signed an exclusive distribution agreement. Precision Lens will be Leica’s exclusive channel partner for ophthalmic surgical microscopes and digital imaging equipment for the OR in select geographies in the U.S. Midwest.
- Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Programhttps://modernod.com/news/lineage-cell-therapeutics-presents-encouraging-data-on-vision-restoration-program/2477041/Lineage Cell Therapeutics announced today that Igor Nasonkin, PhD, Principal Investigator and Director of R&D, served as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the company’s Vision Restoration Program at Neu
- Market Scope: Advancing Technology Drives Ophthalmic OR Microscope Market to 6 Percent Growth by 2024https://modernod.com/news/market-scope-advancing-technology-drives-ophthalmic-or-microscope/2476746/Manufacturers continue to push the envelope integrating advanced technology into the surgical suite with their top-of-the-line ophthalmic OR microscopes, bringing 4K and 3-D heads-up display with integrated diagnostics—for those who can afford the price tag. Market Scope expects the global